» Articles » PMID: 30607618

Pigment Epithelium-derived Factor (PEDF) Reduced Expression and Synthesis of SOST/sclerostin in Bone Explant Cultures: Implication of PEDF-osteocyte Gene Regulation in Vivo

Overview
Specialty Endocrinology
Date 2019 Jan 5
PMID 30607618
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in Serpinf1 gene which encodes pigment epithelium-derived factor (PEDF) lead to osteogenesis imperfecta type VI whose hallmark is defective matrix mineralization. We reported previously that PEDF reduced expression and synthesis of Sost/Sclerostin as well as other osteocytes genes encoding proteins that regulate matrix mineralization [1]. To determine whether PEDF had an effect on osteocyte gene expression in bone, we used bone explant cultures. First, osteocytes were isolated from surgical waste of bone fragments obtained from patients undergoing elective foot surgeries under approved IRB protocol by Penn State College of Medicine IRB committee. Primary osteocytes treated with PEDF reduced expression and synthesis of Sost/Sclerostin and matrix phosphoglycoprotein (MEPE) as well as dentin matrix protein (DMP-1). On the whole, PEDF reduced osteocyte protein synthesis by 50% and by 75% on mRNA levels. For bone explants, following collagenase digestion, bone fragments were incubated in alpha-MEM supplemented with 250 ng/ml of PEDF or BSA. After 7 days of incubation in a medium supplemented with PEDF, analysis of mRNA by PCR and protein by western blotting of encoded osteocyte proteins showed reduced Sclerostin synthesis by 39% and MEPE by 27% when compared to fragments incubated in medium supplemented with BSA. mRNA expression levels of osteocytes in bone fragments treated with PEDF were reduced by 50% for both SOST and MEPE when compared to BSA-treated bone fragments. Taken together, the data indicate that PEDF has an effect on osteocyte gene expression in bone and encourage further studies to examine effect of PEDF on bone formation indices in animal models and its effect on osteocyte gene expression in vivo following PEDF administration.

Citing Articles

Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types.

Jovanovic M, Guterman-Ram G, Marini J Endocr Rev. 2021; 43(1):61-90.

PMID: 34007986 PMC: 8755987. DOI: 10.1210/endrev/bnab017.


Ex vivo Bone Models and Their Potential in Preclinical Evaluation.

Cramer E, Ito K, Hofmann S Curr Osteoporos Rep. 2021; 19(1):75-87.

PMID: 33428030 PMC: 7935733. DOI: 10.1007/s11914-020-00649-5.

References
1.
Dawson D, Volpert O, Gillis P, Crawford S, Xu H, BENEDICT W . Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999; 285(5425):245-8. DOI: 10.1126/science.285.5425.245. View

2.
Sekiya H, Mikuni-Takagaki Y, Kondoh T, Seto K . Synergistic effect of PTH on the mechanical responses of human alveolar osteocytes. Biochem Biophys Res Commun. 1999; 264(3):719-23. DOI: 10.1006/bbrc.1999.1582. View

3.
Gowen L, Petersen D, Mansolf A, Qi H, Stock J, Tkalcevic G . Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2002; 278(3):1998-2007. DOI: 10.1074/jbc.M203250200. View

4.
Winkler D, Sutherland M, Geoghegan J, Yu C, Hayes T, Skonier J . Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22(23):6267-76. PMC: 291840. DOI: 10.1093/emboj/cdg599. View

5.
Gu G, Nars M, Hentunen T, Metsikko K, Vaananen H . Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res. 2005; 323(2):263-71. DOI: 10.1007/s00441-005-0066-3. View